Arca Biopharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ABIO Nasdaq 2834 http://arcabio.com/ 1.20 Stock Up +0.03

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arca Biopharma Inc

ARCA biopharma to Present at the Sidoti & Company Fall 2017 Conference - Sep 21st, 2017 6:30 am
ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial - Aug 16th, 2017 6:30 am
ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis - Aug 9th, 2017 2:30 pm
ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update - Aug 3rd, 2017 2:15 pm
ARCA biopharma Announces 200th Patient Randomized into the GENETIC-AF Seamless Design Phase 2B/3 Clinical Trial - Apr 26th, 2017 6:30 am
ARCA biopharma to Present at the Planet MicroCap Showcase 2017 Investor Conference - Apr 18th, 2017 6:30 am
ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update - Mar 21st, 2017 2:30 pm
ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial - Mar 6th, 2017 6:30 am
Anders Hove, MD Joins ARCA biopharma Board of Directors - Feb 21st, 2017 6:30 am
ARCA biopharma to Present at Biotech Showcase 2017 - Jan 4th, 2017 6:30 am
StockNewsNow.com Publishes New SNNLive Video Interview with ARCA biopharma, Inc. Provides Company Overview and Discusses Clinical Development - Nov 15th, 2016 6:30 am
ARCA biopharma Announces Third Quarter 2016 Financial Results and Provides Business Update - Nov 14th, 2016 2:15 pm
ARCA biopharma Announces Randomization of First European Patients in GENETIC-AF Phase 2B/3 Clinical Trial - Oct 6th, 2016 6:30 am